argenx SE has achieved a dramatic financial inflection, with Q2 2026 revenue surging 197% year-over-year to $2.8 billion, driven by the rapid global adoption of VYVGART. This scale has unlocked best-in-class profitability, with operating margins expanding to 3...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has accelerated to 197% year-over-year in Q2 2026, driving gross margins to a best-in-class 90.1% and operating margins to 30.1%, demonstrating powerful operating leverage as the commercial model scales.
VYVGART generated over $4.1 billion in 2025, nearly doubling year-on-year, showcasing strong revenue growth.
New clinical data presented at the 2026 American Academy of Neurology meeting demonstrated VYVGART's efficacy in treating ocular myasthenia gravis and broader MG subtypes.
argenx SE operates in key international markets including the United States, Japan, China, and the Netherlands, enhancing its revenue potential.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 23, 2026 | $7.32+16.7% vs $6.27 | $2.8B+49.8% vs $1.9B |
Q2 2026 May 7, 2026 | $5.90+14.3% vs $5.16 | $3.2B+121.8% vs $1.4B |
Q1 2026 Feb 26, 2026 | $8.02+48.2% vs $5.41 | $2.4B+79.6% vs $1.3B |
Q4 2025 Oct 30, 2025 | $5.18+18.5% vs $4.37 | $948M-25.7% vs $1.3B |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Bristol Myers Squibb (BMY) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company's Board of Directors.
Tidal Investments LLC lifted its position in argenex SE (NASDAQ: ARGX) by 97.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,362 shares of the company's stock after purchasing an additional 1,168 shares during the period. Tidal
argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark ARGX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for argenx SE (ARGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $945.82 | $60.92B | 48.18 | 89.64% | 31.11% | 20.15% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $246.51 | $32.91B | 105.80 | 65.19% | 16.82% | 93.61% | — | |
| $18.95 | $2B | -2.66 | 15.58% | -6.93% | -9.96% | — | |
| $62.21 | $12.02B | 34.56 | 12.87% | 2.14% | 1.18% | — | |
| $43.93 | $7.3B | -18.46 | 33.87% | -64.64% | -110.84% | — |
argenx SE (ARGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ARGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
argenx SE (ARGX) stock FAQ — growth, dividends, profitability & financials explained
argenx SE (ARGX) reported $8.32B in revenue for fiscal year 2025. This represents a 570237% increase from $1.5M in 2011.
argenx SE (ARGX) grew revenue by 89.6% over the past year. This is strong growth.
Yes, argenx SE (ARGX) is profitable, generating $3.00B in net income for fiscal year 2025 (31.1% net margin).
argenx SE (ARGX) has a return on equity (ROE) of 20.2%. This is excellent, indicating efficient use of shareholder capital.
argenx SE (ARGX) generated $1.63B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
